SUBLIVAC FIX Phleum Pratense DT/DRF

Phase 2

Completed

• Conditions: Allergic Rhinitis; Allergic Rhinoconjunctivitis
• Interventions: Biological: Placebo; Biological: SUBLIVAC FIX phleum prat.

• Registration Number: NCT01682070
• Lead Sponsor: HAL Allergy

Brief Summary

The aim of the study is to determine the optimal effective dose of SUBLIVAC FIX Phleum pratense based on reduction of upper airways reactivity after 5 months of treatment with different dosages of SUBLIVAC FIX Phleum pratense compared to placebo. Furthermore, safety and tolerability will be assessed by the number of related Adverse Events of different dosages of SUBLIVAC FIX Phleum pratense compared to placebo.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-09
• Study First Submitted: 2012-09-06
• Study First Submitted QC: 2012-09-07
• Study First Posted: 2012-09-10
• Status Verified: 2013-05
• Primary Completion: 2013-05
• Study Completion: 2013-05
• Last Update Submitted: 2013-05-28
• Last Update Posted: 2013-05-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 266

Inclusion Criteria

• Signed informed consent
• Age ≥ 18 ≤ 60 years
• Allergic rhinitis/rhinoconjunctivitis related to grass pollen with or without concomitant mild to moderate persistent asthma
• FEV1 > 70% for patients with a history of asthma, FEV > 70% or PEF > 80% for patients without a history of asthma
• A positive SPT (mean wheal diameter ≥ 3mm compared to negative control and negative control should be negative) for grass pollen assessed within 1 year before randomization.
• Positive serum specific anti-grass IgE-test (> 0.7 U/mL)
• A positive TNPT for grass pollen at screening (Lebel score ≥ 6) at ≤10,000 AU/mL

Exclusion Criteria

• Patients with (expected) clinically relevant symptoms during the course of the trial due to concomitant sensitization i.e. positive SPT (mean wheal diameter ≥ 3mm) to allergens other than grass pollen
• Patients sensitized to pets should not be included if they are regularly exposed to pets and are symptomatic upon exposure to pets
• Completed immunotherapy (SCIT or SLIT) with grass pollen allergens within the past 5 years
• Completed unsuccessful specific immunotherapy in the past
• Vaccination within one week before start of therapy or during the initiation phase
• Anti-IgE therapy within the 6 months prior to inclusion and during the study
• Severe immune disorders (including auto-immune diseases) and/or diseases requiring immunosuppressive drugs
• Active malignancies or any malignant disease during the previous 5 years
• Severe uncontrolled diseases that could increase the risk for patients participating in the study, including but not limited to: cardiovascular insufficiency, any severe or unstable lung diseases, endocrine diseases, clinically significant renal or hepatic diseases, or haematological disorders
• Active inflammation or infection of the target organs (nose, eyes or lower airways) at the start of the study
• Moderate to severe nasal obstructive diseases that preclude a TNPT (septal deviation, nasal polyps, recent nasal surgery, etc.)
• Diseases with a contraindication for the use of Adrenaline (e.g. hyperthyroidism, glaucoma)
• Use of systemic steroids within 4 weeks before start of the study and during the study
• Treatment with systemic and local β-blockers
• Participation in a clinical study with a new investigational drug within the last 3 months or for a biological within the last 6 months prior to or during the study
• Pregnancy, lactation or inadequate contraceptive measures for women of child-bearing age (adequate contraceptive measures will be the use of a contraceptive device or -pill)
• Alcohol, drug or medication abuse within the past year
• Any clinically significant abnormal laboratory parameter at screening
• Lack of cooperation or compliance
• Severe psychiatric, psychological, or neurological disorders
• Patients who are employees of the institution or 1st grade relatives or partners of the investigator

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
SUBLIVAC FIX Phleum prat. 0 AUN/ml	Placebo	-
SUBLIVAC FIX Phleum prat. 3,333 AUN/ml	SUBLIVAC FIX phleum prat.	-
SUBLIVAC FIX phleum prat. 10,000 AUN/ml	SUBLIVAC FIX phleum prat.	-
SUBLIVAC FIX phleum prat. 20,000 AUN/ml	SUBLIVAC FIX phleum prat.	Evaluation of the SUBLIVAC FIX Phleum prat. 20,000 AUN/ml by an independent safety committee
SUBLIVAC FIX Phleum prat. 40,000 AUN/ml	SUBLIVAC FIX phleum prat.	Start of SUBLIVAC FIX Phleum prat. 40,000 AUN/ml arm depends on safety in the SUBLIVAC FIX Phleum prat. 20,000 AUN/ml arm evaluated by an independent safety committee

Primary Outcome Measures

Name	Time	Method
Nasal Provocation Test (NPT)	5 months
Number of related AEs	First ten days of study medication intake

Secondary Outcome Measures

Name	Time	Method
Serum specific immunoglobulin levels (IgE, IgG, IgG4)	5 months
Number of local and systemic reactions	Duration of study medication intake (approximately 5 months)
Peak Nasal Inspiratory Flow (PNIF)	5 months

Trial Locations

Locations (22)

SP-ZOZ Ośrodek Zdrowia w Bieńkówce; 🇵🇱 Bieńkówka, Poland

Poradnia Alergologiczna Samodzielnego Publicznego Szpitala Nr 5 Slaskiego Uniwersytetu Medycznego w Katowicach; 🇵🇱 Katowice, Poland

Poradnia Alergologii i Chorób Płuc SP ZOZ Uniwersytecki Szpital Kliniczny im Norberta Barlickiego w Łodzi; 🇵🇱 Lodz, Poland

EMC Intytut Medyczny S.A. Przychodnia przy Łowieckiej; 🇵🇱 Wrocław, Poland

NZOS "Zdrowie"; 🇵🇱 Cieszyn, Poland

NZOZ Lekarze Specjaliści J. Małolepszy i Partnerzy; 🇵🇱 Wrocław, Poland

NZOZ Centrum Alergologii; 🇵🇱 Łódź, Poland

Centrum Alergologii Teresa Hofman; 🇵🇱 Poznań, Poland

ALERGOMED Specjalistyczna Przychodnia Lekarska Sp. z o.o.; 🇵🇱 Tarnów, Poland

Dres.Ina Röhrig-Petering und Holger Petering; 🇩🇪 Hildesheim, Germany

ALERGOPNEUMA Marek Michnar i Wspolnicy Sp. Jawna; 🇵🇱 Lublin, Poland

Charité Universitaetsmedizin Berlin Klinik f. Dermatalogie, Venerologie u. Allergologie, Campus Charité Mitte; 🇩🇪 Berlin, Germany

Klinik u. Poliklinik f. Dermatologie u. Allergologie Universität Bonn; 🇩🇪 Bonn, Germany

CIMS Studienzentrum Bamberg; 🇩🇪 Bamberg, Germany

Klinikum Stuttgart - Klinik f. Dermatologie u. Allergologie; 🇩🇪 Stuttgart, Germany

Universitäts- Hautklinik Eberhard Karls - Universität Tübingen Department of Dermatology; 🇩🇪 Tübingen, Germany

Dermatologikum Hamburg - Dept. of Allergology; 🇩🇪 Hamburg, Germany

FÄ HNO Allergologie; 🇩🇪 Saalfeld /Saale, Germany

Klinikum der Johann-Wolfgang-Goethe Universität - Zentrum f. Kinder- u. Jugendmedizin; 🇩🇪 Hessen, Germany

Dr. Med. Ulrich Neumann; 🇩🇪 Wolmirstedt, Germany

Prywatna Praktyka Lekarska Gabinet Pediatryczno-Alergologiczny; 🇵🇱 Białystok, Poland

HNO Praxis Dr. Horn/Dr. Zeuner; 🇩🇪 Heidelberg, Germany